NCT05143996
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
At risk: Primary completion moved at least 2 years 10 months later, primary endpoint(s) modified.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 9 versions: 8 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion dates pushed to Dec 30, 2029 Show 8 more changesShow less
- Primary endpoint(s) modified
- Phase changed: Phase 1 → Phase 1/2
- Enrollment increased: 60 → 275 participants
- Eligibility criteria shortened, about 228 words
- Trial sites expanded: 11 → 17 locations
- Trial arms changed: 3 → 5
- Study description expanded, about 97 words
- Secondary endpoints shortened, about 3 words
- Minor Site contacts updated at 1 of 11 sitesv8
- Notable Primary completion date: Aug 2025 to Jan 2027
- Study sites: 7 to 11
- Study completion date: Nov 2025 to Jun 2027
- Minor Site details revised at 1 of 7 sitesv6
- Minor Site details revised at 5 of 7 sitesv4
Show 2 earlier versionsHide 2 earlier versions
- Minor Site details revised at 1 of 7 sitesv3
Notable Enrollment target: 9 to 60v2 Show 7 more changesShow less
- Primary completion date: Jul 2022 to Aug 2025
- Eligibility criteria shortened, about 286 words
- Study sites: 4 to 7
- Study completion date: Jul 2022 to Nov 2025
- Study description expanded, about 103 words
- Study arms: 1 to 3
- Study title expanded, about 4 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Arms and interventions
Patients with relapsed/refractory AML or MDS will receive CLN-049 via IV administration
Patients with relapsed/refractory AML or MDS will receive CLN-049 via IV administration
Patients with relapsed/refractory AML or MDS will receive CLN-049 via SC injection
Dose Optimization: patients will be randomized 1:1 to one of two dose regimens of CLN-049 via IV derived from doses tested during Part B (MAD-IV). Dose Expansion: patients will receive a single dose regimen of CLN-049 via IV as determined by Dose Optimization (RP2D).
Newly diagnosed, previously untreated AML patients with TP53 mutations will receive a single dose regimen of CLN-049 via IV as determined by Dose Optimization (RP2D).
Drugs: CLN-049
Sites
17 sites in 1 country